Clinical Trials Browser

Phase 2 × Radium-223 × 90 days × Clear all

NCT02225704 2026-04-13

Radium-223 in Combination With Enzalutamide

Phase 2 Completed

Prostatic Neoplasms

NCT04206319 2026-03-16

Radium-223 in Biochemically Recurrent Prostate Cancer

Phase 2 Active not recruiting

Biochemical Recurrent Prostate Cancer

NCT04704505 2026-02-06

BAT-RAD

Phase 2 Recruiting

Prostate Adenocarcinoma